SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
May 31, 2022
Date of Report (date of earliest event reported)
Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
149 Commonwealth Drive, Menlo Park, CA 94025
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Common Stock, $0.001 par value||CORT||The Nasdaq Stock Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders
On May 31, 2022, we held our annual meeting of stockholders to consider and vote on proposals: 1) to elect nine directors to hold office until our 2023 annual meeting of stockholders, 2) to approve the Corcept Therapeutics Incorporated Amended and Restated 2012 Incentive Award Plan, and 3) to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
A total of 106,249,716 shares of Corcept Therapeutics Incorporated common stock held by stockholders of record at the close of business on April 13, 2022 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 97,532,419. The voting on the three matters is set forth below:
Proposal 1 — Election of Directors. The following directors were elected to serve until our 2023 annual meeting of stockholders.
|G. Leonard Baker, Jr.||70,597,281||13,586,534||13,348,604|
|Joseph K. Belanoff, M.D.||83,809,681||374,134||13,348,604|
|Gillian M. Cannon, Ph.D.||82,052,091||2,131,724||13,348,604|
|David L. Mahoney||72,563,105||11,620,710||13,348,604|
|Joshua M. Murray||83,865,037||318,778||13,348,604|
|Daniel N. Swisher, Jr.||72,184,474||11,999,341||13,348,604|
|James N. Wilson||80,854,416||3,329,399||13,348,604|
Proposal 2 — The Corcept Therapeutics Incorporated Amended and Restated 2012 Incentive Award Plan was not approved.
Proposal 3 — The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022 was ratified.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|CORCEPT THERAPEUTICS INCORPORATED|
|Date:||June 2, 2022||By:||/s/ Atabak Mokari|
|Name: Atabak Mokari|
|Title: Chief Financial Officer and Treasurer|